ESC 22 Late-breaker Discussion: The INVICTUS Trial

ESC Congress 22 — Late-breaker host, Dr Harriette Van Spall(McMaster University, CA) invited Dr Ganesan Karthikeyan (All India Institute of Medical Sciences, IN) to share the latest data from the INVICTUS trial (NCT02832544).

This randomized, open-label, non-inferiority trial compared rivaroxaban (Xarelto, Bayer) versus standard vitamin K antagonists (VKA) (Warfarin) therapy in 4,500 patients diagnosed with rheumatic heart disease.

Recorded on-site at ESC Congress 2022, Barcelona.